A5102822871- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Malaria Research and Control
- Virology and Viral Diseases
- Viral Infections and Outbreaks Research
- Insect symbiosis and bacterial influences
- Aquaculture disease management and microbiota
- Invertebrate Immune Response Mechanisms
International Centre for Genetic Engineering and Biotechnology
2016-2023
Centro de Ingeniería Genética y Biotecnología
2020
Background Dengue is one of the fastest spreading vector-borne diseases, caused by four antigenically distinct dengue viruses (DENVs). Antibodies against DENVs are responsible for both protection as well pathogenesis. A vaccine that safe and efficacious in all people irrespective their age domicile still an unmet need. It becoming increasingly apparent design must eliminate epitopes implicated induction infection-enhancing antibodies. Methodology/principal findings We report a Pichia...
Four antigenically distinct serotypes (1–4) of dengue viruses (DENVs) cause disease. Antibodies to any one DENV serotype have the potential predispose an individual more severe disease upon infection with a different serotype. A vaccine must elicit homotypic neutralizing antibodies all four avoid risk such antibody-dependent enhancement in recipient. This is formidable challenge as evident from lack protective efficacy against DENV-2 by tetravalent live attenuated that has completed phase...
BackgroundA tetravalent live attenuated dengue vaccine, Dengvaxia, sensitised naïve recipients to severe illness upon a subsequent natural infection and is suspected be due antibody-dependent enhancement (ADE). ADE has also been implicated in the neurological outcomes of Zika virus (ZIKV) infection. It become evident that cross-reactive antibodies targeting viral pre-membrane protein fusion-loop epitope are ADE-competent. A pre-clinical sub-unit vaccine candidate, DSV4, eliminates these...
ABSTRACT Zika virus (ZIKV) is an arbovirus which shares antigenic similarity and the mosquito vector with dengue viruses (DENVs). ZIKV a neurotropic capable of causing congenital neurodevelopmental birth defects. As antibodies (Abs) can potentially enhance infection by DENVs, preventive vaccine must be designed to eliminate antibody dependent enhancement infection. We developed Subunit Vaccine (ZSV) consisting two proteins, ZS S, in genetically pre-determined ratio 1:4, using methylotrophic...
BackgroundZika virus (ZIKV), an arbovirus capable of causing neurological abnormalities, is a recognised human pathogen, for which vaccine required. As ZIKV antibodies can mediate antibody-dependent enhancement (ADE) dengue (DENV) infection, must not only protect against but also sensitise vaccinees to severe dengue.MethodsThe N-terminal 80% envelope protein (80E) was expressed in Pichia pastoris and its capacity self-assemble into particulate structures evaluated using dynamic light...
While most vaccines aim to develop a solid humoral and neutralizing antibody response against the pathogen, an effective vaccine candidate should be able stimulate both B-cell mediated immunity, T-cell cellular immunity. The focus of vaccinology is rapidly gaining generate T cell responses, which can mediate pathogen clearance help B cells leading protective responses. Here we evaluate immune pre-clinical tetravalent dengue subunit candidate, DSV4, in mice. have shown previously that DSV4...
Background: Dengue is caused by four antigenically distinct serotypes of dengue viruses, DENV-1, -2, -3 and -4. A tetravalent live attenuated vaccine, Dengvaxia, sensitised naïve recipients to severe illness upon a subsequent natural infection that suspected be due antibody-dependent enhancement (ADE). ADE has also been implicated in the neurological outcomes Zika virus (ZIKV) infection. It become evident cross-reactive antibodies targeting viral pre-membrane protein fusion-loop epitope are...